Zhao Daidi, Zhang Wenting, Ma Xue, Zhao Runze, Yao Lingling, Lu Jiarui, Yan Xu, Bai Miao, Zhang Guoxun, Li Hongzeng, Guo Jun
Department of Neurology, Tangdu Hospital, Air Force Medical University, Xi'an 710038, China.
Xijing Hospital of Digestive Disease, Air Force Medical University, Xi'an, China.
Vaccine X. 2023 Sep 21;15:100388. doi: 10.1016/j.jvacx.2023.100388. eCollection 2023 Dec.
This study aims to evaluate the short-term safety of inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in Chinese patients with central nervous system inflammatory demyelinating diseases (CNS IDDs).
A web-based survey was conducted among patients with CNS IDDs from April 15 to 19, 2022 in China. In total, 645 patients with CNS IDDs were identified, including 425 patients with multiple sclerosis (MS), 194 with neuromyelitis optica spectrum disorder (NMOSD), and 26 with other CNS IDDs. The questionnaire consisted of demographic data, clinical records, history of SARS-CoV-2 vaccination, and vaccination-related symptoms within one month after vaccination. The demographic data, clinical information, and relapse rates between vaccinated and non-vaccinated patients were compared.
Among 645 patients with CNS IDDs, 78 were vaccinated and 567 were non-vaccinated with the vaccination rate of 12.1 %. Compared to non-vaccinated group, a lower percentage of patients on DMDs therapy (41.0 % vs. 71.8 %, < 0.001) and an increased proportion of patients with other vaccination in past 3 years (17.9 % vs. 4.8 %, < 0.001) were observed in vaccinated group. Six patients experienced a relapse within 30 days of a vaccination. Additionally, vaccine-associated relapse rates in vaccinated patients did not significantly differ from these in non-vaccinated patients among 2020, 2021, and from January 1 to October 1, 2022.
No increased risk of vaccination-associated relapses among Chinese patients with CNS IDDs indicated that inactivated SARS-CoV-2 vaccines appear to be safe for this population.
本研究旨在评估新型冠状病毒2（SARS-CoV-2）灭活疫苗在中国中枢神经系统炎性脱髓鞘疾病（CNS IDD）患者中的短期安全性。
2022年4月15日至19日在中国对CNS IDD患者进行了一项基于网络的调查。共确定了645例CNS IDD患者，其中包括425例多发性硬化症（MS）患者、194例视神经脊髓炎谱系障碍（NMOSD）患者和26例其他CNS IDD患者。问卷包括人口统计学数据、临床记录、SARS-CoV-2疫苗接种史以及接种后1个月内的疫苗相关症状。比较了接种和未接种患者的人口统计学数据、临床信息和复发率。
在645例CNS IDD患者中，78例接种了疫苗，567例未接种，接种率为12.1%。与未接种组相比，接种组接受疾病修饰治疗药物（DMDs）治疗的患者比例较低（41.0%对71.8%，<0.001），过去3年接受其他疫苗接种的患者比例有所增加（17.9%对4.8%，<0.001）。6例患者在接种疫苗后30天内复发。此外，在2020年、2021年以及2022年1月1日至10月1日期间，接种疫苗患者的疫苗相关复发率与未接种患者的复发率无显著差异。
中国CNS IDD患者中与疫苗接种相关的复发风险没有增加，这表明SARS-CoV-2灭活疫苗对该人群似乎是安全的。
